Sponsors & Partners
Global Sponsor
Deloitte
Life sciences and health care is transforming and moving at an unprecedented rate of change. From strategy to delivery, Deloitte’s life sciences and health care industry group combines cutting-edge, creative solutions with trusted business and technology acumen to help navigate, define and deliver tomorrow’s digital business, today. Our capabilities, together with industry insights and experience across the health care ecosystem, can help guide organizations to stay ahead of health care transformation and prepare for the Future of Health™.
Global Clinical Research Partner
.png)
ICON plc
ICON plc is a global provider of outsourced drug development and commercialisation solutions and services to pharmaceutical, biotechnology, medical device, and government and public health organisations. The company specialises in the strategic development, management and analysis of programs that support clinical development. ICON offers a full range of consulting, development and commercialisation services that help clients to accelerate the development of drugs and devices that save lives and improve quality of life.
Lead Sponsors
.png)
Amgen
Amgen is one of the world’s leading biotechnology companies. Amgen is a values-based company, deeply rooted in science and innovation to transform new ideas and discoveries into medicines for patients with serious illnesses.
Cytiva
Cytiva is a global life sciences leader with more than 7,000 associates across 40 countries dedicated to advancing and accelerating therapeutics.
Formerly GE Healthcare Life Sciences, Cytiva is a trusted partner to customers that undertake life-saving activities ranging from biological research to developing innovative vaccines, biologic drugs, and novel cell and gene therapies.
Cytiva brings speed, efficiency and capacity to research and manufacturing workflows, enabling the development, manufacture and delivery of transformative medicines to patients.
Ipsen
Ipsen is a global mid-size biopharmaceutical company with a focus on transformative medicines in Oncology, Neuroscience and Rare Disease. Under the overarching theme of Focus. Together. For patients & society, Ipsen will be prioritizing how to accelerate innovation and drive positive impact for patients, employees, shareholders and society. With total sales over €2.5 billion in 2020, Ipsen sells more than 20 medicines in over 110 countries, with a direct commercial presence in more than 30 countries. Ipsen’s R&D is focused on its innovative and differentiated technological platforms located in the heart of the leading biotechnological and life sciences hubs (Paris-Saclay, France; Oxford, UK; Cambridge, US; Shanghai, China). The Group has about 5,700 employees worldwide.
About the Janssen Pharmaceutical Companies of Johnson & Johnson
At Janssen, we’re creating a future where disease is a thing of the past. We’re the Pharmaceutical Companies of Johnson & Johnson, working tirelessly to make that future a reality for patients everywhere by fighting sickness with science, improving access with ingenuity, and healing hopelessness with heart. We focus on areas of medicine where we can make the biggest difference: Cardiovascular & Metabolism, Immunology, Infectious Diseases & Vaccines, Neuroscience, Oncology, and Pulmonary Hypertension.
Learn more at www.janssen.com.
Follow us at www.twitter.com/JanssenGlobal.
.png)
Medidata
Medidata is leading the digital transformation of life sciences, creating hope for millions of patients. Medidata helps generate the evidence and insights to help pharmaceutical, biotech, medical device and diagnostics companies, and academic researchers accelerate value, minimize risk, and optimize outcomes. More than one million registered users across 1,400 customers and partners access the world's most-used platform for clinical development, commercial, and real-world data. Medidata, a Dassault Systèmes company (Euronext Paris: #13065, DSY.PA), is headquartered in New York City and has offices around the world to meet the needs of its customers.
Medidata and Medidata Rave are registered trademarks of Medidata Solutions, Inc., a wholly owned subsidiary of Dassault Systèmes.
Zur Rose Group
Zur Rose Group is Europe’s largest e-commerce pharmacy and one of the leading medical wholesalers in Switzerland. It also operates the leading marketplace in southern Europe for consumer health, beauty and personal care products commonly sold in pharmacies. The company is internationally present with strong brands, including Germany’s best-known pharmacy brand, DocMorris, and employs more than 2,200 people at sites in Switzerland, Germany, the Netherlands, Spain and France. Now serving over 11 million active customers in core European markets, Zur Rose Group generated revenue of CHF 1,752 million (including Medpex and Apotal) in 2020.
With its business model, the Zur Rose Group offers high-quality, safe and cost- effective pharmaceutical care. It also excels in continuous development of digital healthcare services and as a platform technology provider.
Through recent acquisitions (e.g. Teleclinic, the largest telehealth company in Germany), its technology companies EHealth-Tec and BlueCare, deals (Joint venture with leading Swiss health insurers to create a digital health platform) and collaboration on priority chronic conditions (e.g. with the pharmaceutical company Novo Nordisk on obesity), Zur Rose Group is actively driving forward its positioning as a comprehensive healthcare service provider, with focus on building up the DocMorris European healthcare ecosystem brand, networking qualified providers of products, services and digital solutions.
Associate Sponsors
Airfinity
Airfinity provides global health intelligence and predictive analytics that decision makers can trust, understand and act upon to save lives.
Airfinity is a life science analytics company. Trusted by some of the world’s largest pharma companies, government agencies, corporates and investors, Airfinity has established itself as an authoritative provider of predictive insights and accurate, independent information.
The choice of R&D priorities, drug investment, a health policy to pursue or a treatment to prescribe have a direct impact on lives. At Airfinity, we recognise the gravity of these decisions.
We provide scenario planning tools and forecasts that can be understood, relied upon and used for decision making.
The core of our approach is to combine automated global monitoring of new science, policies, media, KOLs, social media and broader health databases with multiple human Q&A processes by expert analysts in real time.
Biogen
At Biogen, our mission is clear: we are pioneers in neuroscience. Biogen discovers, develops, and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. One of the world’s first global biotechnology companies, Biogen was founded in 1978 by Charles Weissmann, Heinz Schaller, Kenneth Murray, and Nobel Prize winners Walter Gilbert and Phillip Sharp. Today, Biogen has the leading portfolio of medicines to treat multiple sclerosis, has introduced the first approved treatment for spinal muscular atrophy, commercializes biosimilars of advanced biologics, and is focused on advancing research programs in multiple sclerosis and neuroimmunology, Alzheimer’s disease and dementia, neuromuscular disorders, movement disorders, ophthalmology, neuropsychiatry, immunology, acute neurology, and neuropathic pain.
Qatar Foundation – Unlocking Human Potential
Qatar Foundation for Education, Science and Community Development (QF) is a non-profit organization that supports Qatar on its journey to becoming a diversified and sustainable economy. QF began cultivating an R&D landscape in Qatar over 15 years ago, and today, QF’s investment in Research, Development and Innovation (RDI) is integral to addressing current global challenges – from climate change to food security; AI to cybersecurity; integrated healthcare to precision medicine. QF views RDI as vital for Qatar’s transition from a hydrocarbon economy to one where the production of services and goods is based on intellectual capital.
QF was founded in 1995 by His Highness Sheikh Hamad bin Khalifa Al Thani, the Father Amir, and Her Highness Sheikha Moza bint Nasser, who shared the vision to provide Qatar with quality education. Today, QF’s world-class education system offers lifelong learning opportunities to community members as young as six months through to doctoral level, enabling graduates to thrive in a global environment and contribute to the nation’s development.
QF is also creating a multidisciplinary innovation hub in Qatar, where homegrown researchers are working to address local and global challenges. By promoting a culture of lifelong learning and fostering social engagement through programs that embody Qatari culture, QF is committed to empowering the local community and contributing to a better world for all.
For a complete list of QF’s initiatives and projects, please visit: www.qf.org.qa
THREAD
THREAD’s platform helps unlock the power of your decentralized studies. Sponsors and CROs can remotely capture data from participants and sites during, in between and in lieu of in-clinic visits — securely through one unified platform.
.png){kind=spacer}
TraceLink
TraceLink is a network-based platform company that leverages its digital supply network and digital network platform to bend the supply chain around the patient. Through its industry-leading digital supply network, the TraceLink Digital Network Platform can enable seamless data sharing and process orchestration across the entire healthcare industry, enabling the creation of a real-time, patient-driven supply network to ensure that every patient gets the medicines they need, when they need them, safely and securely.
Since 2009, TraceLink has been building the world's largest track and trace network, with a comprehensive global track and trace platform, natively integrated with Amazon Web Services, and designed to minimize risk, cost and time in meeting diverse and evolving global track and trace requirements.
TraceLink's powerful Digital Supply Network provides visibility into the path of pharmaceutical products traveling through the supply chain. The 275,000+ members on the TraceLink network range from pharmaceutical companies, contract manufacturing organizations, wholesale distributors, parallel importers, repackagers, third-party logistics providers, pharmacies, hospitals, clinics and physician offices.
Supporting Partners
© Financial Times Live
FT Live and its journalism are subject to a self-regulation regime under the FT Editorial Code of Practice